Professor Bob Hancock
R.E.W. (Bob) Hancock OC, OBC, FRSC. He is a Professor of Microbiology & Immunology, UBC, an Associate Faculty Member of the Wellcome Trust Sanger Institute and a Canada Research Chair in Health and Genomics. His research interests include small cationic peptides as novel antimicrobials and modulators of innate immunity, the development of novel treatments for antibiotic resistant infections, the systems biology of innate immunity, inflammatory diseases and Pseudomonas aeruginosa, and antibiotic uptake and resistance. He has published more than 670 papers and reviews, has 55 patents awarded, and is an ISI highly cited author in Microbiology with more than 65,000 citations and an h-index of 133. He has won several awards including the Aventis Pharmaceuticals ICAAC Award, the leading award for research on antimicrobials, and Canada’s three top prizes for Health Research, and is an Officer of the Order of Canada. He was a co-founder of Migenix, Inimex Pharmaceuticals, ABT Innovations, Sepset, and the Centre for Drug Research and Development.